AJG — Arthur J. Gallagher & Co.

Wall Street is constructive: consensus is Buy/Moderate Buy with a 12-month target around $284.5, and Morgan Stanley and Argus recently raised targets to $290-$300. Q2 adjusted EPS of $2.84 beat the $2.82 consensus, but the slight revenue miss, the initial 4.6% post-earnings drop, the 1.84% slide on 2026-08-27, and a planned $3.24M insider sale keep sentiment from being exuberant.

Top-line growth has accelerated sharply on M&A: YoY revenue growth went from roughly 11-15% in 2024 to 16-34% in 2025 and 24-28% in 2026, while core organic growth held around 6%. Reported GAAP profitability has gone the other way—TTM operating margin fell from about 21% a year ago to 17%, and Q2 2026 GAAP EPS was $1.25 vs $1.40 a year earlier—because acquisition-related amortization and integration costs are running through reported results. That is an integration/accounting distortion, not a demand collapse: adjusted EPS continues to grow, and Q2 2026 free cash flow of -$41M was much better than -$466M in Q2 2025, consistent with normal seasonal bonus and working-capital timing.

At $260.15, GAAP trailing P/E of 42.6 looks expensive, but TTM GAAP EPS of $6.11 is depressed by acquisition amortization. P/S of 4.24 is below AJG's 5-year average of 4.77, and on next-FY consensus adjusted EPS of $13.245 the forward P/E is about 19.6x. That is fair, not cheap: a justified premium to most financials, but not a bargain relative to its own history. The PEG ratio is negative and not meaningful here.

At 19.6x forward adjusted EPS, the market is pricing in continued mid-single-digit organic growth and successful M&A, but not a dramatic acceleration. The stock has already de-rated from $313.55 to $260.15 while estimates have moved up, so a reversion to a 22x forward multiple would imply roughly $291. If adjusted EPS grows around 12% and the multiple merely holds, the stock still works. The bear case is organic growth slipping below ~5% and multiple compression to 17-18x, which would put fair value in the $225-240 area.

As of 2026-08-27, RSI was 54.89—neutral, not overbought or oversold. Price was 1.92% above the 20-day SMA, 4.96% above the 50-day SMA, and 11.32% above the 200-day SMA, so the intermediate trend remains up. Support is around the 50-day at roughly $248 and the 200-day at roughly $234; resistance is the $270-272 area and then $290+. No strong short-term entry signal, but a pullback toward $248 would improve risk/reward.

• P&C pricing is flattening, especially in property lines, and surplus-lines stamping data show moderating premium growth; this likely keeps organic growth in mid-single digits rather than reaccelerating sharply.
• Interest-rate direction matters for fiduciary investment income on client premium trust funds; a falling-rate cycle is a mild headwind to investment income but not to core fee revenue.
• The M&A market remains active but competitive; Gallagher's scale and cost of capital give it an advantage, but deal pricing and integration are execution risks.
• Commercial insurance market conditions—capacity, casualty pricing trends, and loss-cost inflation—drive new-business opportunity and client retention.

• Q3 2026 earnings in late October: evidence that organic growth holds around 6% and GAAP margins begin normalizing as acquisition amortization and integration costs fade.
• New bolt-on M&A announcements or integration updates from the large recent acquisition; successful accretion would support the premium multiple.
• Further analyst estimate revisions and target-price increases, following Morgan Stanley and Argus moves in August 2026.

• Faster-than-expected P&C pricing deceleration; organic growth below roughly 5% would undermine the current multiple.
• Acquisition integration and amortization drag: GAAP EPS will continue to look soft, and any visible integration stumble could spook the quality premium.
• Multiple compression from the current ~19.6x forward adjusted EPS to 17-18x would put the stock in the $225-240 range.
• Interest-rate cuts reducing fiduciary investment income, which supplements brokerage revenue.

AJG is a high-quality compounder—roughly 6% organic growth, a $66.8B market cap, low reported leverage, resilient fee-based brokerage, and a deep M&A pipeline—so the long-term thesis is intact. At $260.15 the stock is not a bargain, but valuation is reasonable relative to its own history and the quality of the franchise; patient investors can hold or add on weakness toward $250. This is analysis, not personalized investment advice.

Applied a 22x forward P/E multiple to consensus next-fiscal-year adjusted EPS of $13.245, yielding $291.39. The 22x multiple is a modest premium to the current ~19.6x forward multiple, justified by AJG's ~6% organic growth, M&A engine, strong cash conversion, and P/S below its 5-year average, while still accounting for moderating P&C pricing momentum.